United Therapeutics Corporation (UTHR): A Bull Case Theory [Yahoo! Finance]
United Therapeutics Corporation (UTHR)
Last united therapeutics corporation earnings: 4/29 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.unither.com/investor-relations
Company Research
Source: Yahoo! Finance
United Therapeutics Corporation's share was trading at $471.99 as of January 15th. UTHR's trailing and forward P/E were 17.89 and 15.15 respectively according to Yahoo Finance. Phovoir/Shutterstock.com United Therapeutics Corporation is a commercial-stage biotechnology company built around treprostinil, a prostacyclin analogue that drives its leadership in pulmonary arterial hypertension through multiple differentiated delivery platforms, including Tyvaso, Tyvaso DPI, Remodulin, and Orenitram. Treprostinil's mechanism of action enables direct pulmonary vasodilation, and United Therapeutics has successfully expanded its utility across PAH and PH-ILD, establishing a durable and highly profitable franchise. The next major value driver is the expansion of Tyvaso into idiopathic pulmonary fibrosis without co-morbid pulmonary hypertension, a significantly larger indication with high unmet need. The ex-US TETON-2 Phase 3 trial met its primary endpoint, demonstrating preservation of lun
Show less
Read more
Impact Snapshot
Event Time:
UTHR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UTHR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UTHR alerts
High impacting United Therapeutics Corporation news events
Weekly update
A roundup of the hottest topics
UTHR
News
- JPM26: Jazz sells PRV for $200m, targets deals in 2026 [Yahoo! Finance]Yahoo! Finance
- ReAlta Life Sciences Announces Appointment of Jonathan Rigby to Board of Directors [Yahoo! Finance]Yahoo! Finance
- United Therapeutics (NASDAQ:UTHR) was given a new $645.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.MarketBeat
- United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
UTHR
Earnings
- 10/29/25 - Beat
UTHR
Sec Filings
- 1/15/26 - Form 4
- 1/15/26 - Form 144
- 1/13/26 - Form 4
- UTHR's page on the SEC website